Table 4 Type of therapeutic response in individuals who responded to therapy
Therapy type | All patients (n = 72) | Neurodiagnostic study abnormality (n = 29) | EEG/MRI/CSF normal (n = 43) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SI% | RL% | DC% | PE% | SI% | RL% | DC% | PE% | SI% | RL% | DC% | PE% | |
Antidepressant (n = 45) | 46 | – | 29 (13/45) | 40 (18/45) | 34 | 0 (0/16) | 12 (2/16) | 25 (4/16) | 54 | – | 38 (11/29) | 48 (14/29) |
Antipsychotic (n = 52) | 41 | – | 33 (17/52) | 35 (18/52) | 28 | 0 (0/19) | 5 (1/19) | 21 (4/19) | 49 | – | 48 (16/33) | 43 (14/33) |
Benzodiazepine (n = 63) | 57 | – | 63 (40/63) | 87 (55/63) | 41 | 0 (0/24) | 52 (13/25) | 72 (18/25) | 68 | – | 70 (27/39) | 95 (37/39) |
ECT (n = 49) | 65 | – | 24 (12/49) | 59 (29/49) | 32 | 0 (0/15) | 13 (2/15) | 40 (6/15) | 87 | – | 29 (10/34) | 68 (23/34) |
Nutritional therapy (n = 29) | 0 | – | 0 (0/29) | 0 (0/29) | 0 | 0 (0/13) | 0 (0/13) | 0 (0/13) | 0 | – | 0 (0/10) | 0 (0/10) |
Immunotherapy (n = 43) Steroids IVIg Anti-CD20 MMF/AZ | 68 27 73 33 38 | – – – – – | 48 (58/120) 5 (2/39) 77 (33/43) 58 (11/19) 63 (12/19) | 59 (71/120) 26 (10/39) 88 (38/43) 53 (10/19) 68 (13/19) | 72 36 82 63 75 | 47 (9/19) 0 (0/4) 50 (4/8) 67 (2/3) 75 (3/4) | 58 (43/74) 8 (2/24) 73 (19/26) 100 (11/11) 85 (11/13) | 73 (54/74) 30 (7/24) 96 (25/26) 91 (10/11) 92 (12/13) | 45 20 68 0 20 | – – – – – | 33 (15/46) 0 (0/15) 82 (14/17) 0 (0/8) 17 (1/6) | 37 (17/46) 20 (3/15) 76 (13/17) 0 (0/8) 17 (1/6) |